Table 1 Characteristics of the analyzed test results according to test results and vaccination status

Test results

 Negative

16,090 (100.0)

—

854 (5.3)

635 (3.9)

2,183 (13.6)

9,565 (59.4)

2,853 (17.7)

 Positive

—

3,908 (100.0)

253 (6.5)

162 (4.1)

425 (10.9)

2,219 (56.8)

849 (21.7)

Sex

 Male

6,965 (81.6)

1,567 (18.4)

438 (5.1)

330 (3.9)

1,126 (13.2)

4,953 (58.1)

1,685 (19.7)

 Female

9,125 (79.6)

2,341 (20.4)

669 (5.8)

467 (4.1)

1,482 (12.9)

6,831 (59.6)

2,017 (17.6)

Age group, years

 65–69

902 (68.2)

421 (31.8)

85 (6.4)

74 (5.6)

212 (16.0)

750 (56.7)

202 (15.3)

 70–74

2,226 (75.6)

719 (24.4)

175 (5.9)

115 (3.9)

387 (13.1)

1,759 (59.7)

509 (17.3)

 75–79

3,340 (78.4)

921 (21.6)

194 (4.6)

163 (3.8)

514 (12.1)

2,493 (58.5)

897 (21.1)

 80–84

3,764 (81.2)

869 (18.8)

248 (5.4)

169 (3.6)

598 (12.9)

2,681 (57.9)

937 (20.2)

 ≥ 85

5,858 (85.7)

978 (14.3)

405 (5.9)

276 (4.0)

897 (13.1)

4,101 (60.0)

1,157 (16.9)

Number of comorbidities

 0–1

4,036 (73.1)

1,486 (26.9)

319 (5.8)

208 (3.8)

584 (10.6)

3,341 (60.5)

1,070 (19.4)

 2–4

8,283 (81.7)

1,860 (18.3)

563 (5.6)

364 (3.6)

1,244 (12.3)

6,081 (60.0)

1,891 (18.6)

 ≥ 5

3,771 (87.0)

562 (13.0)

225 (5.2)

225 (5.2)

780 (18.0)

2,362 (54.5)

741 (17.1)

Infection history

 With

1,424 (96.9)

46 (3.1)

977 (5.3)

713 (3.8)

2,201 (11.9)

11,202 (60.5)

3,435 (18.5)

 Without

14,666 (79.2)

3,862 (20.8)

130 (8.8)

84 (5.7)

407 (27.7)

582 (39.6)

267 (18.2)

Residential municipality

 City A

3,792 (79.4)

983 (20.6)

331 (6.9)

222 (4.6)

703 (14.7)

2,662 (55.7)

857 (17.9)

 City B

4,684 (87.4)

678 (12.6)

280 (5.2)

211 (3.9)

655 (12.2)

3,230 (60.2)

986 (18.4)

 City C

7,614 (77.2)

2,247 (22.8)

496 (5.0)

364 (3.7)

1,250 (12.7)

5,892 (59.8)

1,859 (18.9)

Interval since last vaccine dose, mean days (SD)

—

—

—

454.0 (96.7)

235.3 (55.7)

97.0 (28.9)

25.5 (15.6)

Test type

 PCR

8,721 (86.2)

1,391 (13.8)

575 (5.7)

399 (3.9)

1,418 (14.0)

6,136 (60.7)

1,584 (15.7)

 Antigen

7,369 (74.5)

2,517 (25.5)

532 (5.4)

398 (4.0)

1,190 (12.0)

5,648 (57.1)

2,118 (21.4)

Test week

 1 Oct–7 Oct

1,240 (92.5)

101 (7.5)

79 (5.9)

62 (4.6)

248 (18.5)

951 (70.9)

1 (0.1)

 8 Oct–14 Oct

1,019 (92.0)

89 (8.0)

51 (4.6)

48 (4.3)

178 (16.1)

819 (73.9)

12 (1.1)

 15 Oct–21 Oct

1,194 (90.1)

131 (9.9)

61 (4.6)

56 (4.2)

214 (16.2)

972 (73.4)

22 (1.7)

 22 Oct–28 Oct

1,134 (90.3)

122 (9.7)

69 (5.5)

46 (3.7)

187 (14.9)

918 (73.1)

36 (2.9)

 29 Oct–4 Nov

1,072 (83.6)

211 (16.4)

75 (5.8)

44 (3.4)

175 (13.6)

957 (74.6)

32 (2.5)

 5 Nov–11 Nov

1,149 (81.0)

269 (19.0)

58 (4.1)

45 (3.2)

202 (14.2)

1,050 (74.0)

63 (4.4)

 12 Nov–18 Nov

1,344 (81.2)

311 (18.8)

94 (5.7)

71 (4.3)

223 (13.5)

1,135 (68.6)

132 (8.0)

 19 Nov–25 Nov

1,265 (76.0)

400 (24.0)

92 (5.5)

61 (3.7)

224 (13.5)

1,081 (64.9)

207 (12.4)

 26 Nov–2 Dec

1,341 (78.2)

374 (21.8)

103 (6.0)

75 (4.4)

205 (12.0)

987 (57.6)

345 (20.1)

 3 Dec–9 Dec

1,334 (75.6)

431 (24.4)

110 (6.2)

56 (3.2)

193 (10.9)

897 (50.8)

509 (28.8)

 10 Dec–16 Dec

1,288 (72.6)

485 (27.4)

94 (5.3)

76 (4.3)

186 (10.5)

821 (46.3)

596 (33.6)

 17 Dec–23 Dec

1,470 (75.5)

478 (24.5)

124 (6.4)

85 (4.4)

204 (10.5)

662 (34.0)

873 (44.8)

 24 Dec–30 Dec

1,240 (71.0)

506 (29.0)

97 (5.6)

72 (4.1)

169 (9.7)

534 (30.6)

874 (50.1)